Prevalence Of familial hypercholeSTerolaemia (FH) in Italian Patients with coronary artERy disease: The POSTER study

Gulizia, Michele Massimo; Maggioni, Aldo P.; Abrignani, Maurizio Giuseppe; Bilato, Claudio; Mangiacapra, Fabio; Sanchez, Federico; Piovaccari, Giancarlo; Montagna, Laura; Marini, Marco; Biasio, Marzia De; Averna, Maurizio; Casula, Manuela; Colivicchi, Furio; Fabbri, Gianna; Lucci, Donata; Zampoleri, V.; Catapano, Alberico L.; Investigators, Poster

doi:10.1016/j.atherosclerosis.2020.07.007

Cited by 10 publications

(12 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, despite the use of statins, a high prevalence of premature ASCVD has been reported in FH subjects [47]. Therefore, the addition of novel lipid-lowering therapies such PCSK9-i may be helpful in reducing ASCVD risk in FH subjects.…”

Section: Discussionmentioning

confidence: 99%

Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting

et al. 2021

View full text Add to dashboard Cite

Aims Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. Methods In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. Results After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (− 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (− 20.4%, p < 0.05). Finally, simple regression analyses showed that ∆ PWV was significantly associated with ∆ LDL-C (p < 0.01), ∆ NC and ∆ MHR (p value for both < 0.05). Conclusions In conclusion, PCSK9-i therapy significantly improved lipid and inflammatory profiles and PWV values in FH subjects; our results support the positive effect of PCSK9-i in clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting

et al. 2021

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Among these risk factors, patients with FH have a tendency to develop AMI at earlier ages, and patients with FH have double risk of cardiovascular events compared to non-FH patients, even for patients undergoing high-intensity lipid-lowering therapy [ 15 , 16 ]. High LDL-C levels since birth are known to have a correlation with early atherosclerotic disease onset [ 15 ]. Approximately one subject in 250 carries a genetic mutation that determines FH; there should be more representation of FH among subjects who have a documented CAD diagnosis [ 15 ].…”

Section: Discussionmentioning

confidence: 99%

“…High LDL-C levels since birth are known to have a correlation with early atherosclerotic disease onset [15]. Approximately one subject in 250 carries a genetic mutation that determines FH; there should be more representation of FH among subjects who have a documented CAD diagnosis [15]. Therefore, identifying these subjects earlier could lead to improved management of their high cardiovas- High-sensitivity cardiac troponin T 24 0 -14 cular risk, and identify possible FH relatives through cascade screening [15].…”

Section: Discussionmentioning

confidence: 99%

“…Approximately one subject in 250 carries a genetic mutation that determines FH; there should be more representation of FH among subjects who have a documented CAD diagnosis [15]. Therefore, identifying these subjects earlier could lead to improved management of their high cardiovas- High-sensitivity cardiac troponin T 24 0 -14 cular risk, and identify possible FH relatives through cascade screening [15]. On the other hand, despite broad warnings and public information campaigns, smoking is still the most common modifiable risk factor in young adult STEMI patients [17,18].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

ST-Elevation Acute Myocardial Infarction in a Young Man

Usuda¹,

Tanaka²,

Suzuki³

et al. 2022

J Med Cases

View full text Add to dashboard Cite

Acute myocardial infarction (AMI) in young patients is very rare, but the incidence has increased over years past at younger ages, likely due to the presence of multiple risk factors. We present the first known case of ST-elevation AMI (STEMI) in a young man. A 22-year-old Japanese man was transferred to our hospital due to suddenly occurred anterior chest pain. An electrocardiogram revealed ST elevation in anteroseptal leads together with reciprocal ST depression in inferior leads. An emergency coronary angiogram was performed, revealing a 100% occlusion at segment 6 of the coronary artery and we established a diagnosis of STEMI. The lesion was expanded to 0% stenosis through plain old balloon angioplasty, after which a third-generation drug-eluting stent was installed there. Afterwards, the patient was discharged on day 17. In this case, a combination of mild six risk factors plus family history of hypertension might lead to this atypical event.

show abstract

Consensus document on diagnosis and management of familial hypercholesterolemia from the Italian Society for the Study of Atherosclerosis (SISA)

Tarugi,

Bertolini,

Calandra

et al. 2024

Nutrition, Metabolism and Cardiovascular Diseases

View full text Add to dashboard Cite

Prevalence Of familial hypercholeSTerolaemia (FH) in Italian Patients with coronary artERy disease: The POSTER study

Cited by 10 publications

References 26 publications

Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting

Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting

ST-Elevation Acute Myocardial Infarction in a Young Man

Consensus document on diagnosis and management of familial hypercholesterolemia from the Italian Society for the Study of Atherosclerosis (SISA)

Contact Info

Product

Resources

About